Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
PLXP PLx Pharma $5.30 (0.00%) 06:53 05/10/19 05/10 06:53 05/10/19 06:53 Earnings	PLx Pharma reports Q1 EPS ($2.71) with item, consensus (33c) » Reports Q1 revenue $300K,… Reports Q1 revenue $300K, consensus $100K. Q1 EPS includes ($1.47) per share for the beneficial conversion feature and preferred stock dividends related to the Series A $15M convertible preferred stock financing completed in February, and a non-cash charge of (88c) per share as a result of a change in the fair value of the warrant liability. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 May

Over a month ago
PLXP PLx Pharma $5.45 0.04 (0.74%) 04:55 04/23/19 04/23 04:55 04/23/19 04:55 Conference/Events	PLx Pharma management to meet with JMP Securities » Meeting to be held in New… Meeting to be held in New York on April 23 hosted by JMP Securities. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Apr
PLXP PLx Pharma $5.29 (0.00%) 07:01 04/17/19 04/17 07:01 04/17/19 07:01 Conference/Events	PLx Pharma management to meet with JMP Securities » Meeting to be held in New… Meeting to be held in New York on April 23 hosted by JMP Securities. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Apr
PLXP PLx Pharma $5.33 (0.00%) 08:05 04/12/19 04/12 08:05 04/12/19 08:05 Initiation	PLx Pharma initiated at Janney Montgomery Scott » PLx Pharma assumed with a… PLx Pharma assumed with a Buy at Janney Montgomery Scott. Janney Montgomery Scott analyst Esther Hong assumed coverage of PLx Pharma with a Buy rating and $13 fair value estimate. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Apr
PLXP PLx Pharma $5.61 0.13 (2.37%) 17:28 03/27/19 03/27 17:28 03/27/19 17:28 Syndicate	Breaking Syndicate news story on PLx Pharma » PLx Pharma files to sell… PLx Pharma files to sell 5.77M shares of common stock for holders 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

PLXP PLx Pharma $5.54 -0.525 (-8.66%) 09:27 03/25/19 03/25 09:27 03/25/19 09:27 Syndicate	Breaking Syndicate news story on PLx Pharma » PLx Pharma files $75M… PLx Pharma files $75M mixed securities shelf 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AAPL Apple $182.83 1.12 (0.62%) , FLDM Fluidigm $14.12 1.35 (10.57%) … 10:21 03/14/19 03/14 10:21 03/14/19 10:21 Initiation	Fly Intel: Top five analyst initiations » Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Outperform at Cowen. 2. Fluidigm (FLDM) initiated with a Buy at BTIG. 3. Kala Pharmaceuticals (KALA) initiated with a Buy at Jefferies. 4. PLx Pharma (PLXP) initiated with an Outperform at JMP Securities. 5. Walker & Dunlop (WD) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. AAPL Apple $182.83 1.12 (0.62%) FLDM Fluidigm $14.12 1.35 (10.57%) KALA Kala Pharmaceuticals $8.27 0.21 (2.61%) PLXP PLx Pharma $5.77 0.26 (4.72%) WD Walker & Dunlop $51.87 0.37 (0.72%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	14 Mar 19 Mar 26 Mar 09 May 10 May 15 Aug
PLXP PLx Pharma $5.51 0.15 (2.80%) 07:01 03/14/19 03/14 07:01 03/14/19 07:01 Initiation	PLx Pharma initiated at JMP Securities » PLx Pharma initiated with… PLx Pharma initiated with an Outperform at JMP Securities. JMP Securities analyst Donald Ellis initiated PLX Pharma with an Outperform rating and $15 price target, noting that the company's improved formulation of OTC aspirin provides statistically significant superior antiplatelet activity compared to enteric-coated aspirin and lower GI ulcer and bleeding compared to immediate-release aspirin. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a quarter ago
PLXP PLx Pharma $5.11 -0.11 (-2.11%) 07:27 02/19/19 02/19 07:27 02/19/19 07:27 Conference/Events	PLx Pharma to host special shareholder meeting » Special shareholder… Special shareholder meeting, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation, will be held on February 19 at 9 am. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
PLXP PLx Pharma $4.00 -0.525 (-11.60%) 06:04 01/14/19 01/14 06:04 01/14/19 06:04 Downgrade	PLx Pharma rating change at Raymond James » PLx Pharma downgraded to… PLx Pharma downgraded to Market Perform from Outperform at Raymond James 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial